Канал: R3i Foundation

Avances Recientes en la Farmacoterapia de la Retinopatía Diabética en DM tipo 2: Agonistas de PPARɑ.

Avances Recientes en la Farmacoterapia de la Retinopatía Diabética en DM tipo 2: Agonistas de PPARɑ.

What is their relevance to residual macrovascular risk when LDL-C is low?

What is their relevance to residual macrovascular risk when LDL-C is low?

Webinar: Recent Advances in Pharmacotherapy of Diabetic Retinopathy in Type 2 Diabetes Mellitus.

Webinar: Recent Advances in Pharmacotherapy of Diabetic Retinopathy in Type 2 Diabetes Mellitus.

Guidelines for dyslipidemia management of type 2 diabetes – new directions?

Guidelines for dyslipidemia management of type 2 diabetes – new directions?

Advances in diabetes and vascular cognitive impairment.

Advances in diabetes and vascular cognitive impairment.

Novel targets: Does PCSK7 have potential in NAFLD?

Novel targets: Does PCSK7 have potential in NAFLD?

Residual stroke risk in type 2 diabetes: what can we learn from the trials.

Residual stroke risk in type 2 diabetes: what can we learn from the trials.

New insights: PPARα/SPPARMα, stroke and dementia.

New insights: PPARα/SPPARMα, stroke and dementia.

Residual stroke risk in T2D – insights from trials. Does SPPARMα have therapeutic potential?

Residual stroke risk in T2D – insights from trials. Does SPPARMα have therapeutic potential?

Emerging glucose-lowering therapies in type 2 diabetes: insights from the trials.

Emerging glucose-lowering therapies in type 2 diabetes: insights from the trials.

Understanding protective effects in diabetic kidney disease: from biomarkers to clinical outcomes.

Understanding protective effects in diabetic kidney disease: from biomarkers to clinical outcomes.

Reducing cardiovascular risk in type 2 diabetes by glucose lowering – does the drug matter?

Reducing cardiovascular risk in type 2 diabetes by glucose lowering – does the drug matter?

Is liver fat the nexus between diabetic dyslipidemia and CVD?

Is liver fat the nexus between diabetic dyslipidemia and CVD?

What can we learn from the PROMINENT trial?

What can we learn from the PROMINENT trial?

Understanding NAFLD: novel molecular insights.

Understanding NAFLD: novel molecular insights.

PROMINENT and PROMINENT Substudy: Rationale and Update.

PROMINENT and PROMINENT Substudy: Rationale and Update.

Overview of clinical trials with pemafibrate in Japan and Europe.

Overview of clinical trials with pemafibrate in Japan and Europe.

Non-alcoholic fatty liver disease, dyslipidemia and CVD: is liver fat the critical link?

Non-alcoholic fatty liver disease, dyslipidemia and CVD: is liver fat the critical link?

New therapeutic targets in lipids and atherosclerosis: exploring the pipeline.

New therapeutic targets in lipids and atherosclerosis: exploring the pipeline.

How do we interpret the results of PROMINENT? What does it mean for clinical practice?

How do we interpret the results of PROMINENT? What does it mean for clinical practice?

New insights into the metabolism and atherogenicity of TG-rich lipoproteins and their remnants.

New insights into the metabolism and atherogenicity of TG-rich lipoproteins and their remnants.

New pathways linking cholesterol efflux to inflammasome activation.

New pathways linking cholesterol efflux to inflammasome activation.

TG-rich lipoproteins and their remnants: why are they atherogenic and how best to assess this?

TG-rich lipoproteins and their remnants: why are they atherogenic and how best to assess this?

Can changes in lifestyle impact residual vascular risk?

Can changes in lifestyle impact residual vascular risk?

Targeting cholesterol: what is new?

Targeting cholesterol: what is new?

Insights from the 2nd International Steering Committee meeting.

Insights from the 2nd International Steering Committee meeting.

Triglyceride-rich lipoproteins and remnant cholesterol: unmet clinical needs.

Triglyceride-rich lipoproteins and remnant cholesterol: unmet clinical needs.

Molecular and clinical insights of diabetic retinopathy.

Molecular and clinical insights of diabetic retinopathy.

Emerging target: PCSK7

Emerging target: PCSK7

Inflammation in residual risk.

Inflammation in residual risk.

The effects of pemafibrate on macrophage activation and vascular inflammation.

The effects of pemafibrate on macrophage activation and vascular inflammation.

Why is residual microvascular risk an unmet clinical need?

Why is residual microvascular risk an unmet clinical need?

How important is residual inflammatory risk to residual vascular risk?

How important is residual inflammatory risk to residual vascular risk?

Albuminuria: a marker for clinical action.

Albuminuria: a marker for clinical action.

Diabetic retinopathy: molecular and clinical insights.

Diabetic retinopathy: molecular and clinical insights.

Why are hyperglycaemia-related microvascular complications so often underestimated?

Why are hyperglycaemia-related microvascular complications so often underestimated?

How has consumption of high and low energy drinks changed in Mexican women?

How has consumption of high and low energy drinks changed in Mexican women?

Can changes in lifestyle impact residual vascular risk?

Can changes in lifestyle impact residual vascular risk?

What are the recommended secondary lipid targets in Japanese patients with type 2 diabetes?

What are the recommended secondary lipid targets in Japanese patients with type 2 diabetes?

What are the recommended LDL-C targets for Japanese population for primary and secondary prevention?

What are the recommended LDL-C targets for Japanese population for primary and secondary prevention?

Dr. Nabil Seidah discusses the burden of familial hypercholesterolaemia and why PCSK9 is important.

Dr. Nabil Seidah discusses the burden of familial hypercholesterolaemia and why PCSK9 is important.

What functions are regulated by convertases?

What functions are regulated by convertases?

What is hyperApoB and why is it important to clinical practice?

What is hyperApoB and why is it important to clinical practice?

Adiponectin is a hormone secreted by adipose tissue, reduced in obesity. What is its principal role?

Adiponectin is a hormone secreted by adipose tissue, reduced in obesity. What is its principal role?

What is the mechanistic link between inflammation and the metabolic cluster?

What is the mechanistic link between inflammation and the metabolic cluster?

What is inflammation relevant to the pathogenesis of insulin resistance?

What is inflammation relevant to the pathogenesis of insulin resistance?

What is the level of cardiovascular residual risk in Asian population?

What is the level of cardiovascular residual risk in Asian population?

What are the criteria for overweight and obesity in Japan?

What are the criteria for overweight and obesity in Japan?

What is the value of BMI as a marker of risk?

What is the value of BMI as a marker of risk?

Gut microbiota is a complex ecological system. How does it interact with our metabolism?

Gut microbiota is a complex ecological system. How does it interact with our metabolism?

What can we learn from past clinical trials to test new agents for residual vascular risk?

What can we learn from past clinical trials to test new agents for residual vascular risk?

What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?

What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?

Will genetic risk scores have a role in clinical management in the future?

Will genetic risk scores have a role in clinical management in the future?

What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?

What is your perspective of the results of the REDUCE-IT trial with high dose eicosapentaenoic acid?

What is residual vascular risk – and what are the markers of this risk?

What is residual vascular risk – and what are the markers of this risk?

Does visceral obesity have other clinical consequences?

Does visceral obesity have other clinical consequences?

What treatments are available now for managing triglycerides – and what are the issues?

What treatments are available now for managing triglycerides – and what are the issues?

How has genetics helped to identify new targets for managing triglycerides?

How has genetics helped to identify new targets for managing triglycerides?

Are triglycerides related to cardiovascular risk?

Are triglycerides related to cardiovascular risk?

What is on the horizon for the treatment of high triglycerides?

What is on the horizon for the treatment of high triglycerides?

Why are elevated triglycerides linked with increased inflammation? How can we address this risk?

Why are elevated triglycerides linked with increased inflammation? How can we address this risk?

What should clinicians measure: triglycerides or something else?

What should clinicians measure: triglycerides or something else?

Do we have evidence for the ‘inflammatory hypothesis’ in atherosclerosis?

Do we have evidence for the ‘inflammatory hypothesis’ in atherosclerosis?

Why is inflammation important to residual vascular risk?

Why is inflammation important to residual vascular risk?

What is residual vascular risk?

What is residual vascular risk?

Why do we need a new consensus on residual vascular risk? Has the risk profile changed?

What are the limitations of the fibrate trials in residual vascular risk?

What are the limitations of the fibrate trials in residual vascular risk?

OMEGA-3, REDUCE-IT and VITAL

OMEGA-3, REDUCE-IT and VITAL

Why are apolipoprotein B levels measured in PROMINENT?

Why are apolipoprotein B levels measured in PROMINENT?

Why does visceral obesity drive risk for diabetes and cardiovascular disease?

Why does visceral obesity drive risk for diabetes and cardiovascular disease?

Why do we need new approaches to manage atherogenic dyslipidemia?

Why do we need new approaches to manage atherogenic dyslipidemia?

What is the critical test for the SPPARMα concept?

What is the critical test for the SPPARMα concept?

What is the focus of the Residual Risk Reduction Initiative?

What is the focus of the Residual Risk Reduction Initiative?

What is the SPPARMα concept?

What is the SPPARMα concept?

Why do we need new treatments for managing the obesity-driven dysmetabolic state?

Why do we need new treatments for managing the obesity-driven dysmetabolic state?

How can we improve on current treatments for high triglycerides?

How can we improve on current treatments for high triglycerides?

What’s new in hypertriglyceridemia: insights from genetic studies.

What’s new in hypertriglyceridemia: insights from genetic studies.

The obesity crisis, what drives dyslipidemia? A focus on triglyceride-rich lipoprotein metabolism.

The obesity crisis, what drives dyslipidemia? A focus on triglyceride-rich lipoprotein metabolism.

What is the therapeutic potential for a SPPARMα?

What is the therapeutic potential for a SPPARMα?

What features differentiate a SPPARMα from a fibrate?

What features differentiate a SPPARMα from a fibrate?

What does the SPPARMα concept offer for management of residual vascular risk?

What does the SPPARMα concept offer for management of residual vascular risk?

Selective PPARα modulation: understanding the concept and its therapeutic potential.

Selective PPARα modulation: understanding the concept and its therapeutic potential.

Effect of SPPARMα on atherogenic triglyceride-rich lipoproteins at increased concentrations.

Effect of SPPARMα on atherogenic triglyceride-rich lipoproteins at increased concentrations.

What new approaches for managing atherogenic dyslipidemia are on the horizon?

What new approaches for managing atherogenic dyslipidemia are on the horizon?

New Horizons in Residual Vascular Risk: The SPPARMα Concept

New Horizons in Residual Vascular Risk: The SPPARMα Concept

Effects of SPPARMα agonism on lipid and glucose metabolism in T2D and hypertriglyceridaemia patients

Effects of SPPARMα agonism on lipid and glucose metabolism in T2D and hypertriglyceridaemia patients

What is changing in the management of residual cardiovascular risk?

What is changing in the management of residual cardiovascular risk?

How to identify which patients benefit most from additional intervention beyond current treatment?

How to identify which patients benefit most from additional intervention beyond current treatment?

What is the effect of SPPARMα on HDL?

What is the effect of SPPARMα on HDL?

How does the safety profile with this SPPARMα agent – pemafibrate - differ from the fibrates?

Understanding how pemafibrate acts: the SPPARMα movie by R3i

Understanding how pemafibrate acts: the SPPARMα movie by R3i

Barriers to the Screening Programme & How They Were Overcome

Barriers to the Screening Programme & How They Were Overcome

Diabetic Retinopathy & General Practitioners

Diabetic Retinopathy & General Practitioners

What are the criteria for overweight and obesity in Japan?

What are the criteria for overweight and obesity in Japan?

What is the level of cardiovascular residual risk in Asian population?

What is the level of cardiovascular residual risk in Asian population?

An Intro to the Residual Risk Reduction Initiative (R3i)

An Intro to the Residual Risk Reduction Initiative (R3i)

What is the value of BMI as a marker of risk?

What is the value of BMI as a marker of risk?

ANITSCHKOW PRIZE 2008: PPAR alpha at the crossroads of obesity, diabetes and cardiovascular disease

ANITSCHKOW PRIZE 2008: PPAR alpha at the crossroads of obesity, diabetes and cardiovascular disease

R3i

R3i

How interpret the results of ACCORD Glucose and ACCORD blood pressure arms on diabetic retinopathy?

How interpret the results of ACCORD Glucose and ACCORD blood pressure arms on diabetic retinopathy?

What are the design and the aim of the Fremantle Diabetes Study?

What are the design and the aim of the Fremantle Diabetes Study?

Could you comment on endpoints used in ACCORD Eye and in the FIELD Ophthalmology Substudy ?

Could you comment on endpoints used in ACCORD Eye and in the FIELD Ophthalmology Substudy ?

In the IDEAL study, what were your findings?

In the IDEAL study, what were your findings?

The STENO-2 study: addressing the issue of Residual Risk

The STENO-2 study: addressing the issue of Residual Risk

Lessons from the main statin trials

Lessons from the main statin trials

What are the recommended LDL-C targets for primary and secondary prevention in Japan?

What are the recommended LDL-C targets for primary and secondary prevention in Japan?

How does one convince authorities of the utility of a programme with a "non-result”?

How does one convince authorities of the utility of a programme with a "non-result”?

Can you discuss how the NHS sensitizes physicians to prevention?

Can you discuss how the NHS sensitizes physicians to prevention?

How to Better Identify Patients at Cardiovascular Residual Risk?

How to Better Identify Patients at Cardiovascular Residual Risk?

Communicating about cardiovascular risk

Communicating about cardiovascular risk

What are the main findings of the United Kingdom Prospective Diabetes Study (UKPDS) ?

What are the main findings of the United Kingdom Prospective Diabetes Study (UKPDS) ?

New Evidence Quantifying Residual Vascular Risk: Update From the PROCAM Study

New Evidence Quantifying Residual Vascular Risk: Update From the PROCAM Study

Current Evidence on Factors Producing Residual Vascular Risk: What are the modifiable risk factors?

Current Evidence on Factors Producing Residual Vascular Risk: What are the modifiable risk factors?

Reducing Dyslipidemia-related Cardiovascular Disease: A Global Problem

Reducing Dyslipidemia-related Cardiovascular Disease: A Global Problem

What are the prevalence and incidence of diabetic retinopathy?

What are the prevalence and incidence of diabetic retinopathy?

Microvascular risk and diabetic nephropathy : an overview

Microvascular risk and diabetic nephropathy : an overview

The REALIST R3i Studies: Recent Research Findings Micro-vascular Residual Risk

The REALIST R3i Studies: Recent Research Findings Micro-vascular Residual Risk

The REALIST R3i Studies: Recent Research Findings on Macro-vascular Residual Risk

The REALIST R3i Studies: Recent Research Findings on Macro-vascular Residual Risk

New Evidence Quantifying Residual Vascular Risk: Update From the PROCAM Study

New Evidence Quantifying Residual Vascular Risk: Update From the PROCAM Study

What is the natural history of diabetic retinopathy?

What is the natural history of diabetic retinopathy?

What are the results of the National screening program implanted in the UK?

What are the results of the National screening program implanted in the UK?